You are advising Hoffmann-LaRoche, which has set up Roche Partnering to manage more than 190 alliances in the healthcare industry. What is the greatest risk that might cause those alliances to be unstable or break apart?

a. One or more of the 190 partners in Roche Partnering could gain access to another company's proprietary knowledge base, technologies, or trade secrets. one or Anticipated gains for Roche

b. Partnering may fail to materialize due to a poor fit in terms of the combination of resources and capabilities.

c. A partner obtains access to another partner's proprietary knowledge base, technologies, or trade secrets.

d. Any or all of the 190 partners in Roche Partnering could become overly dependent on other companies within the partnership.

e. Anticipated gains may fail to materialize for Roche Partnering due to an overly optimistic view of the synergies.

Question

Business

Schaefer

22 August, 03:47

You are advising Hoffmann-LaRoche, which has set up Roche Partnering to manage more than 190 alliances in the healthcare industry. What is the greatest risk that might cause those alliances to be unstable or break apart?

a. One or more of the 190 partners in Roche Partnering could gain access to another company's proprietary knowledge base, technologies, or trade secrets. one or Anticipated gains for Roche

b. Partnering may fail to materialize due to a poor fit in terms of the combination of resources and capabilities.

c. A partner obtains access to another partner's proprietary knowledge base, technologies, or trade secrets.

d. Any or all of the 190 partners in Roche Partnering could become overly dependent on other companies within the partnership.

e. Anticipated gains may fail to materialize for Roche Partnering due to an overly optimistic view of the synergies.

+1

Answers (1)

Know the Answer?

Jadyn Gates · Answer 1

a. One or more of the 190 partners in Roche Partnering could gain access to another company's proprietary knowledge base, technologies, or trade secrets. one or Anticipated gains for Roche partnering may fail to materialize due to a poor fit interms of the combination resources and capabilities.